| Nov 22 |
Sage Therapeutics price target lowered to $4 from $7 at BofA
|
| Nov 21 |
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
|
| Nov 21 |
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
|
| Nov 21 |
Sage ends dalzanemdor development following Phase II trial failure
|
| Nov 21 |
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
|
| Nov 21 |
Sage raised to sector perform by RBC in wake of drug failure
|
| Nov 20 |
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
|
| Nov 20 |
Sage slips as Huntington’s Disease therapy fails in mid-stage trial
|
| Nov 20 |
Sage’s string of research failures continues
|
| Nov 20 |
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
|
